Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.33 |
| ▸ | WNT3A | P56704 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27491921 | 0.85 | DYRK1A (0.42) | DYRK1AMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL30917349 | 0.85 | MEN1 (0.60) | DYRK1AMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL506532 | 0.85 | MEN1 (0.60) | DYRK1AMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL355077 | 0.81 | DYRK1A (0.49) | DYRK1AMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL2621292 | 0.81 | LMNA (0.48) | DYRK1AMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL6598569 | 0.81 | MEN1 (0.47) | DYRK1AMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL3815115 | 0.81 | DYRK1A (0.45) | DYRK1AMEN1ALDH1A1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL29585867 | 0.79 | DYRK1A (0.47) | DYRK1AMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL8221522 | 0.78 | LMNA (0.49) | DYRK1AMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL5548267 | 0.78 | DYRK1A (0.42) | DYRK1AMEN1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124698-A1 | ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-19 | — | — | WO | disclosed |
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
| EP-1752455-B1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2010-11-10 | — | — | EP | disclosed |
| US-7807694-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1317451-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
| US-6472394-B1 | MCH antagonists and their use in the treatment of obesity | SCHERING CORPORATION | 2002-10-29 | — | — | US | disclosed |
| WO-2002051809-A1 | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
| US-6124343-A | Substituted phenyl compounds with a substituent having a thienyl ring | RHONE-POULENC RORER LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| EP-0805802-B1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LTD (GB) | 2000-08-16 | — | — | EP | disclosed |
| US-6048893-A | Substituted phenyl compounds with a substituent having A 1,3-benzodioxole ring | RHONE-POULENC RORER LIMITED (GB) | 2000-04-11 | — | — | US | disclosed |
| EP-0805802-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE-POULENC RORER LIMITED (GB) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022978-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LIMITED (GB) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | DYRK1A 3635/4885MEN1 4239/4885ALDH1A1 2806/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | DYRK1A 4719/4885MEN1 4602/4885ALDH1A1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.